MEDICALSYSTEM(SZ:300439) Zheng Quan Zhi Xing·2025-05-30 10:48Summary of Key Points Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management to enhance fund efficiency while ensuring that the investment projects' funding needs are met [1][4][7]. Group 1: Fundraising Overview - The company raised a total of RMB 599,999,925.00 by issuing 39,999,995 shares at RMB 15 per share, with a net amount of RMB 586,603,698.59 after deducting issuance costs [1]. - The funds are stored in a special account designated for this issuance, managed under a regulatory agreement with banks and the sponsor [2]. Group 2: Fund Utilization and Idle Reasons - As of May 29, 2025, the company has utilized RMB 58,660.37 million of the total RMB 62,233.01 million allocated for the in vitro diagnostic product R&D and industrialization project [2]. - The company anticipates temporary idleness of funds due to the phased nature of project construction, leading to a plan for cash management of idle funds [2][4]. Group 3: Previous Cash Management - The company previously approved the use of up to RMB 10,000 million of idle funds for cash management, with the authorization expiring on March 14, 2025 [3][4]. - The company has not engaged in further cash management activities since the expiration of the previous authorization [4]. Group 4: Current Cash Management Plan - The company intends to continue using up to RMB 10,000 million of idle funds for cash management, with the new authorization valid for 12 months from board approval [4][5]. - The investment will focus on low-risk financial products, ensuring no funds are used for high-risk securities or derivatives [5][6]. Group 5: Decision-Making Process - The board and supervisory committee have approved the cash management plan, ensuring it aligns with regulatory requirements and does not harm shareholder interests [6][7]. - The company will maintain strict oversight and risk control measures during the investment process [6][7].